SCHEMBL3006909

SCHEMBL3006909

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3ccc(Cl)c(Cl)c3)CC2)n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.47
MAPT P10636 2/20 0.47
USP2 O75604 2/20 0.47
RECQL P46063 1/20 0.47
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
TSHR P16473 3/20 0.45
GLA P06280 1/20 0.45
MAPK1 P28482 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 2/20 0.42
HSD11B1 P28845 2/20 0.42
MCOLN3 Q8TDD5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003954 0.92 MAPT (0.49) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3015412 0.92 MEN1 (0.54) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3015038 0.91 HSD17B10 (0.57) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3015005 0.90 MAPT (0.46) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3007925 0.90 MEN1 (0.46) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3003540 0.90 HSD11B1 (0.49) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3015477 0.89 MAPT (0.47) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3009159 0.89 MAPT (0.47) HSD17B10MAPTUSP2RECQLLMNA
SCHEMBL3008465 0.88 SMN1; SMN2 (0.49) MAPTUSP2LMNASMN1; SMN2HTT
SCHEMBL3013485 0.88 MAPT (0.58) HSD17B10MAPTUSP2RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD17B10 2553/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.